Company research
Regencell Bioscience Holdings Ltd
CIK 1829667Updated Nov 18, 2026
RGC price & chart
Loading TradingView…
NASDAQ:RGC on TradingView ↗About the company
We are an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. Our goal is to save and improve the lives of the patients, their families and caregivers and become a market leader for natural and holistic treatments for neurological disorders globally.
In the news
Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm ↗
Portnoy Law Firm Announces Class Action on Behalf of Regencell Bioscience Holdings Limited Investors ↗
Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC ↗
Recent filings
Show 5 more recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 14,729,559Source | 5,755,582Source | 8,438,211Source | 12,621,755Source |
| Property, Plant and Equipment, NetUSD | 135,112Source | 215,434Source | 141,734Source | 440,829Source |
| Current assets: | ||||
| Assets, CurrentUSD | 14,223,157Source | 4,902,813Source | 8,114,013Source | 11,621,343Source |
| Operating Lease, Right-of-Use AssetUSD | 295,620Source | 544,385Source | 84,780Source | 451,084Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,380,194Source | 895,308Source | 219,512Source | 632,320Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 4,959Source | 4,945Source | 130Source | 130Source |
| Retained Earnings (Accumulated Deficit)USD | -36,903,057Source | -25,201,116Source | -21,616,903Source | -17,315,066Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -45,262Source | -64,786Source | -45,766Source | -86,658Source |
| Stockholders' Equity Attributable to ParentUSD | 13,349,365Source | 4,860,274Source | 8,218,699Source | 12,030,333Source |
| Additional Paid in Capital, Common StockUSD | 50,292,725Source | 30,121,231Source | 29,881,238Source | 29,431,927Source |
| Liabilities and EquityUSD | 14,729,559Source | 5,755,582Source | 8,438,211Source | 12,621,755Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,320,695Source | 663,673Source | 193,578Source | 606,914Source |
| Operating Lease, Liability, CurrentUSD | 236,312Source | 312,780Source | 59,807Source | 438,263Source |
| Operating Lease, Liability, NoncurrentUSD | 59,499Source | 231,635Source | 25,934Source | 25,406Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | — | — | -40,898Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,073,596Source | 348,354Source | 125,328Source | 158,081Source |
| Short-term InvestmentsUSD | — | 2,477,900Source | 5,000,000Source | 10,000,000Source |
cash flow · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -11,701,941Source | -3,584,213Source | -4,363,221Source | -6,062,329Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 3,225,583Source | 244,808Source | 449,311Source | 922,623Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -7,695,530Source | -3,113,576Source | -4,001,687Source | -4,962,949Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 2,504,038Source | 2,686,216Source | 5,242,624Source | 58,978Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 152,689Source | 5,376Source | 27,392Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 16,945,925Source | — | 102,282Source | 134,913Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 11,773,340Source | -542,120Source | 1,396,440Source | -4,852,203Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 14,192,455Source | 2,419,115Source | 2,961,235Source | 1,564,795Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 18,907Source | -114,760Source | 53,221Source | -83,145Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 3,226,000Source | 245,000Source | 449,000Source | — |
| DepreciationUSD | 80,908Source | 77,692Source | 305,780Source | 293,135Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | -1,415Source |
| General and Administrative ExpenseUSD | 10,418,348Source | 2,813,682Source | 3,545,066Source | 4,429,379Source |
| Investment Income, InterestUSD | 22,520Source | 185,772Source | 248,000Source | 85,400Source |
| Net Income (Loss) Attributable to ParentUSD | -11,701,941Source | -3,584,213Source | -4,301,837Source | -5,871,130Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -61,384Source | -191,199Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -5,957,788Source |
| Operating ExpensesUSD | 11,724,461Source | 3,769,985Source | 4,736,726Source | 6,273,671Source |
| Proceeds from Issuance of Common StockUSD | 18,620,000Source | — | — | — |
| Proceeds from Noncontrolling InterestsUSD | — | — | 102,282Source | 134,913Source |
| Proceeds from Stock Options ExercisedUSD | 102,561Source | — | — | — |
income statement · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -11,724,461Source | -3,769,985Source | -4,736,726Source | -6,273,671Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -11,701,941Source | -3,584,213Source | -4,363,221Source | -6,062,329Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -61,384Source | -191,199Source |
| Net Income (Loss) Attributable to ParentUSD | -11,701,941Source | -3,584,213Source | -4,301,837Source | -5,871,130Source |
| Earnings Per Share, BasicUSD per share | -2.37Source | -0.72Source | -0.33Source | 0.45Source |
| Earnings Per Share, DilutedUSD per share | -2.37Source | -0.72Source | -0.33Source | -0.45Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 494,603,400Source | 494,488,908Source | 13,012,866Source | 13,012,866Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 494,603,400Source | 494,488,908Source | 13,012,866Source | 13,012,866Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 10,418,348Source | 2,813,682Source | 3,545,066Source | 4,429,379Source |
| Investment Income, InterestUSD | 22,520Source | 185,772Source | 248,000Source | 85,400Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -5,957,788Source |
| Operating ExpensesUSD | 11,724,461Source | 3,769,985Source | 4,736,726Source | 6,273,671Source |
| Other IncomeUSD | — | — | 373,505Source | 211,342Source |
| Research and Development ExpenseUSD | 1,299,627Source | 948,289Source | 1,066,233Source | 1,581,628Source |
| Selling and Marketing ExpenseUSD | 6,486Source | 8,014Source | 125,427Source | 262,664Source |
Filing attachments
ea029147301ex99-1.htm · 6-K · 2026-05-22
Exhibit 99.1 Regencell Bioscience Holdings Limited Announces Closing of Registered Direct Offering of Ordinary Shares HONG KONG, May 22, 2026 - Regencell Bioscience Holdings Limited (Nasdaq: RGC) (the “Company”) announced the closing of a registered direct offering (the “offering”) of approximately $20.0 million led by a $19 million investment from a new fundamental institutional investor with further participation from Univest Securities, LLC (“Univest”), as previously announced on May 19, 20…
Read attachment ↗ea029147201ex99-1.htm · 6-K · 2026-05-19
Exhibit 99.1 Regencell Bioscience Holdings Limited Announces Registered Direct Offering of Ordinary Shares HONG KONG, May 19, 2026 - Regencell Bioscience Holdings Limited (Nasdaq: RGC) (the “Company”), today announced that it has entered into a definitive agreement with investors for the purchase and sale of an aggregate of 985,222 of the Company’s ordinary share, par value $0.00001 per share (the “ Ordinary Shares”) at a purchase price of $20.30 per Ordinary Share in a registered direct offer…
Read attachment ↗ea028960501ex99-1.htm · 6-K · 2026-05-08
Exhibit 99.1 Regencell Bioscience Holdings Limited Announces First Half 2026 Management Financial Results HONG KONG, May 8, 2026 - Regencell Bioscience Holdings Limited (Nasdaq: RGC) (the “Company”) today announced its unaudited condensed consolidated interim financial results for the six months ended December 31, 2025. UNAUDITED CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS As of As of …
Read attachment ↗ea028960501ex99-2.htm · 6-K · 2026-05-08
Exhibit 99.2 REGENCELL BIOSCIENCE HOLDINGS LIMITED Index to Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets at December 31, 2025 and June 30, 2025 (Unaudited) F-2 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Six Months Ended December 31, 2025 and 2024 (Unaudited) F-3 Condensed Consolidated Statements of Changes in Shareholders’ Equity for the Six Months Ended Decem…
Read attachment ↗ea027698901ex99-1_regencell.htm · 6-K · 2026-02-13
Exhibit 99.1 FORM OF Fifth EXTENSION OF letter of Lock-Up Undertaking Date: From: (the “Optionee”) To: Regencell Bioscience Holdings Limited (the “Company”) References are made in this forth extension of the letter of lock-up undertaking (this “Fifth Extension of Lock-Up Undertaking”) to: An agreement of option to purchase ordinary shares of Regencell Bioscience Holdings Limited dated June 9, 2021, under which the Company granted certain options (the “Options”) to purchas…
Read attachment ↗